Apolipoprotein E (APOE) ɛ4 carriage is the strongest genetic risk factor for sporadic Alzheimer's disease dementia. Clinical guidelines discourage APOE disclosure, but therapeutic advances are changing this. Limited work has assessed knowledge and interest in APOE disclosure in Australian adults, and it remains unclear which characteristics are associated with interest within this sample.
Objective
This study examines knowledge and interest in APOE disclosure among Australian adults. Based on previous estimates, it was hypothesized that ≥50% would be interested in APOE disclosure.
Methods
Cognitively unimpaired middle- and older-aged adults (N = 1421) completed the Knowledge, Interest and Preferences for APOE Testing and Disclosure survey, measuring APOE knowledge, interest in APOE disclosure, and perceived benefits/concerns. Participants completed online assessments measuring demographic, mood, subjective cognitive, Alzheimer's disease literacy, and perceived risk characteristics. Participants were categorized into four groups based on their interest: 1) want to know, 2) interested but need more information to decide, 3) unsure, 4) do not want to know).
Results
Almost half of participants (44.2%) indicated that they had heard of APOE previously. Most participants (82%) were interested in knowing their APOE genotype or wanting more information. Compared to individuals who did not want to know their APOE genotype (114, 7.9%), individuals who wanted to know were younger, female, more likely to report dementia family history, and had greater perceived cognitive and Alzheimer's disease risk.
Conclusions
Interest in APOE disclosure is high among Australian adults, consistent with international estimates. Findings will inform APOE disclosure protocols for Australian adults at-risk of dementia.
RiedelBCThompsonPMBrintonRD. Age, APOE and sex: triad of risk of Alzheimer’s disease. J Steroid Biochem Mol Bol2016; 160: 134–147.
2.
PostSGWhitehousePJBinstockRH, et al.The clinical introduction of genetic testing for Alzheimer disease: an ethical perspective. JAMA1997; 277: 832–836.
3.
GoldmanJSHahnSECataniaJW, et al.Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American college of medical genetics and the national society of genetic counselors. Genet Med2011; 13: 597–605.
4.
RobertsJSTersegnoSM. Estimating and disclosing the risk of developing Alzheimer's disease: challenges, controversies and future directions. Future Neurol2010; 5: 501–517.
5.
Budd HaeberleinSAisenPSBarkhofF, et al.Two randomized phase 3 studies of aducanumab in early Alzheimer’s disease. J Prev Alzheimers Dis2022; 9: 197–210.
6.
Van DyckCHSwansonCJAisenP, et al.Lecanemab in early Alzheimer’s disease. N Engl J Med2022; 388: 9–21.
7.
SimsJRZimmerJAEvansCD, et al.Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA2023; 330: 512–527.
8.
SöderbergLJohannessonMNygrenP, et al.Lecanemab, aducanumab, and gantenerumab — binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for Alzheimer's disease. Neurotherapeutics2023; 20: 195–206.
9.
ReimanEMLangbaumJFleisherAS, et al.Alzheimer's prevention initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis2011; 26: 321–329.
10.
Lopez LopezCTariotPNCaputoA, et al.The Alzheimer's prevention initiative generation program: study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's disease. Alzheimers Dement (N Y)2019; 5: 216–227.
11.
BerkowitzCMosconiLRahmanA, et al.Clinical application of APOE in Alzheimer’s prevention: a precision medicine approach. J Prev Alzheimers Dis2018; 5: 245–252.
12.
Elias-SonnenscheinLSViechtbauerWRamakersIHGB, et al.Predictive value of APOE ε4 allele for progression from MCI to AD-type dementia: a meta-analysis. J Neurol Neurosurg Psychiatry2011; 82: 1149.
13.
LimYYMorminoEC. APOE Genotype and early β-amyloid accumulation in older adults without dementia. Neurology2017; 89: 1028–1034.
14.
CummingsJApostolovaLRabinoviciGD, et al.Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis2023; 10: 362–377.
15.
AlberJPopescuDThompsonLI, et al.Safety and tolerability of APOE genotyping and disclosure in cognitively normal volunteers from the butler Alzheimer’s prevention registry. J Geriatr Psychiatry Neurol2022; 35: 293–301.
16.
RobertsJSCupplesLARelkinNR, et al.Genetic risk assessment for adult children of people with Alzheimer’s disease: the risk evaluation and education for Alzheimer’s disease (REVEAL) study. J Geriatr Psychiatry Neurol2005; 18: 250–255.
17.
GreenRCRobertsJSCupplesLA, et al.Disclosure of APOE genotype for risk of Alzheimer's disease. N Engl J Med2009; 361: 245–254.
18.
SngWTYeoSNLinBX, et al.Impacts of apolipoprotein E disclosure on healthy Asian older adults: a cohort study. Int Psychogeriatr2019; 31: 1499–1507.
19.
AshidaSKoehlyLMRobertsJS, et al.The role of disease perceptions and results sharing in psychological adaptation after genetic susceptibility testing: the REVEAL study. Eur J Hum Genet2010; 18: 1296–1301.
20.
LargentEABhardwajTAberaM, et al.Disclosing genetic risk of Alzheimer’s disease to cognitively unimpaired older adults: findings from the study of knowledge and reactions to APOE testing (SOKRATES II). J Alzheimers Dis2021; 84: 1015–1028.
21.
MerlHVeronica DohertyKAltyJ, et al.Truth, hope and the disclosure of a dementia diagnosis: a scoping review of the ethical considerations from the perspective of the person, carer and clinician. Dementia2022; 21: 1050–1068.
22.
De WildeAVan BuchemMMOttenRHJ, et al.Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review. Alzheimers Res Ther2018; 10: 72.
23.
RobertsJS. Anticipating response to predictive genetic testing for Alzheimer's disease: a survey of first-degree relatives. Gerontologist2000; 40: 43–52.
24.
RobertsJSBarberMBrownTM, et al.Who seeks genetic susceptibility testing for Alzheimer’s disease? Findings from a multisite, randomized clinical trial. Genet Med2004; 6: 197–203.
25.
GreenRClarkeVThompsonN, et al.Early detection of Alzheimer disease: methods, markers, and misgivings. Alzheimer Dis Assoc Disord1997; 11: S1.
26.
CaselliRJLangbaumJMarchantGE, et al.Public perceptions of presymptomatic testing for Alzheimer disease. Mayo Clin Proc2014; 89: 1389–1396.
27.
RahmanBMeiserBSachdevP, et al.To know or not to know: an update of the literature on the psychological and behavioral impact of genetic testing for Alzheimer disease risk. Genet Test Mol Biomarkers2012; 16: 935–942.
28.
CutlerSJHodgsonLG. To test or not to test: interest in genetic testing for Alzheimer's disease among middle-aged adults. Am J Alzheimers Dis Other Demen2003; 18: 9–20.
29.
HippsYGRobertsJSFarrerLA, et al.Differences between African Americans and whites in their attitudes toward genetic testing for Alzheimer's disease. Genet Test2003; 7: 39–44.
30.
OttBRPelosiMATremontG, et al.A survey of knowledge and views concerning genetic and amyloid positron emission tomography status disclosure. Alzheimers Dement (N Y)2016; 2: 23–29.
31.
GooblarJRoeCMSelsorNJ, et al.Attitudes of research participants and the general public regarding disclosure of Alzheimer disease research results. JAMA Neurol2015; 72: 1484–1490.
32.
NeumannPJHammittJKMuellerC, et al.Public attitudes about genetic testing for Alzheimer’s disease. Health Aff2001; 20: 252–264.
33.
LimYYYassiNBransbyL, et al.The healthy brain project: an online platform for the recruitment, assessment, and monitoring of middle-aged adults at risk of developing Alzheimer's disease. J Alzheimers Dis2019; 68: 1211–1228.
34.
LimYYAytonDPerinS, et al.An online, person-centered, risk factor management program to prevent cognitive decline: protocol for a prospective behavior-modification blinded endpoint randomized controlled trial. J Alzheimers Dis2021; 83: 1603–1622.
35.
ZigmondASSnaithRP. The hospital anxiety and depression scale. Acta Psychiatr Scand1983; 67: 361–370.
36.
AmariglioREDonohueMCMarshallGA, et al.Tracking early decline in cognitive function in older individuals at risk for Alzheimer disease dementia: the Alzheimer’s disease cooperative study cognitive function instrument. JAMA Neurol2015; 72: 446–454.
37.
OstergrenJEHeeringaSGLeonC, et al.The influence of psychosocial and cognitive factors on perceived threat of Alzheimer’s disease. Am J Alzheimers Dis Other Demen2017; 32: 289–299.
38.
WaterinkLMasselinkLAVan Der LeeSJ, et al.Interest in genetic susceptibility testing and disclosure of AD dementia risk in cognitively normal adults: a survey study. Alzheimers Res Ther2024; 16: 1.
39.
Van Der LeeSJWoltersFJIkramMK, et al.The effect of APOE and other common genetic variants on the onset of Alzheimer's disease and dementia: a community-based cohort study. Lancet Neurol2018; 17: 434–444.
40.
ReynoldsGOTremontGSantorelliGD, et al.Healthy lifestyle behaviors and viewpoints among members of an Alzheimer prevention registry. Alzheimer Dis Assoc Disord2022; 36: 111–117.
41.
NagelAKLoetscherTSmithAE, et al.What do the public really know about dementia and its risk factors?Dementia2021; 20: 2424–2440.
42.
SmithBJAliSQuachH. Public knowledge and beliefs about dementia risk reduction: a national survey of Australians. BMC Public Health2014; 14: 1–10.
43.
KeageHADVillaniGHutchinsonAD. What do young Australian adults know about modifiable risk factors for dementia?BMC Public Health2021; 21: 2166.
44.
RobertsJSMcLaughlinSJConnellCM. Public beliefs and knowledge about risk and protective factors for Alzheimer's disease. Alzheimers Dement2014; 10: S381–S389.
45.
CationsMRadisicGCrottyM, et al.What does the general public understand about prevention and treatment of dementia? a systematic review of population-based surveys. PLoS One2018; 13:e0196085.
46.
HudsonJMPolluxPMMistryB, et al.Beliefs about Alzheimer's disease in Britain. Aging Ment Health2012; 16: 828–835.
47.
StitesSDJohnsonRHarkinsK, et al.Identifiable characteristics and potentially malleable beliefs predict stigmatizing attributions toward persons with Alzheimer’s disease dementia: results of a survey of the US general public. Health Commun2018; 33: 264–273.
48.
WiklerEMBlendonRJBensonJM. Would you want to know? Public attitudes on early diagnostic testing for Alzheimer's disease. Alzheimers Res Ther2013; 5: 1–11.
49.
FrostSMyersLBNewmanSP. Genetic screening for Alzheimer's disease: what factors predict intentions to take a test?Behav Med2001; 27: 101–109.
50.
AlanazyMHAlghsoonKAAlkhodairiAF, et al.Public willingness to undergo presymptomatic genetic testing for Alzheimer’s disease. Neurol Res Int2019; 2019: 2570513.
51.
GoodingHCLinnenbringerELBurackJ, et al.Genetic susceptibility testing for Alzheimer disease: motivation to obtain information and control as precursors to coping with increased risk. Patient Educ Couns2006; 64: 259–267.
52.
BurmesterBLeathemJMerrickP. Subjective cognitive complaints and objective cognitive function in aging: a systematic review and meta-analysis of recent cross-sectional findings. Neuropsychol Rev2016; 26: 376–393.
53.
RobertsSJLaRusseSAKatzenH, et al.Reasons for seeking genetic susceptibility testing among first-degree relatives of people with Alzheimer disease. Alzheimer Dis Assoc Disord2003; 17: 86–93.
54.
EkstractMHoltzmanGIKimKY, et al.Evaluation of a web-based decision aid for people considering the APOE genetic test for Alzheimer risk. Genet Med2017; 19: 676–682.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
